Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

计划入组 40 人 · 首次发布于 2023 年 5 月 6 日

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation

计划入组 128 人 · 首次发布于 2026 年 2 月 24 日

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

计划入组 66 人 · 首次发布于 2018 年 7 月 11 日

FXI-GalNAc-siRNA

IONIS-FXIRX

BAY-2976217

FHI 360

Zambia

FX SHOULDER SOLUTIONS

France

GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.

Taiwan

Waters Receives FDA 510(k) Clearance for BD BACTEC FXI Culture System, Accelerating Bloodstream Infection Diagnostics

CRISPR Therapeutics and Sirius Therapeutics Dose First Patient in Phase 2 Trial of SRSD107 for Venous Thromboembolism Prevention

Sirus Therapeutics' SRSD107 Shows Promise in Phase I siRNA Trial for Thromboembolic Disorders